Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Tripair: a simple, safe and effective tricuspid valve repair solution that breaks barriers to adoption and provides access to patients beyond the reach of existing therapies

Obiettivo

Coramaze Technologies is a clinical-stage medical device company based in Germany, committed to improving the lives of structural heart patients by developing accessible, effective and minimally invasive solutions for tricuspid regurgitation (TR). TR is a life-threatening heart condition affecting approximately 3 million people in Europe. The current treatment landscape is highly limited: medication provides only symptomatic relief and poor long-term prognosis, while open-heart surgery is suitable for less than 1% of patients and is associated with high in-hospital mortality. As a result, more than 90% of TR patients remain untreated, underscoring the scale of the unmet medical need. Transcatheter tricuspid valve interventions (TTVI) offer a promising alternative, but their procedural complexity and strict anatomical requirements have hindered adoption. Today, around half of TR patients cannot be treated or are treated only suboptimally with existing technologies. In response, Coramaze has developed TriPair, a pioneering transcatheter “edge-to-spacer” repair system designed for safe and effective treatment of TR, including complex morphologies that existing devices fail to address. The procedure is completed in less than 30 minutes, requires neither general anesthesia nor transesophageal echocardiography, and combines simplified delivery with atraumatic anchoring and full retrievability. By streamlining workflows and reducing complexity, TriPair overcomes the adoption barriers of current options, which are limited to narrow anatomical subsets and demand specialized imaging expertise. With its simplicity by design, TriPair has the potential to become the first device capable of fully addressing the needs of the large and underserved TR population. Following promising results in the completed FIH study, Coramaze seeks EIC support to fund a EU Pilot Clinical trial on 30 EU patient, to generate European data and advance TriPair to CE marking in Europe.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2025-ACCELERATOR-02

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

CORAMAZE TECHNOLOGIES GMBH
Contributo netto dell'UE
€ 1 757 150,50
Indirizzo
MUHLENHOF 7-9
40721 HILDEN
Germania
PMI
Sì
Regione
Nordrhein-Westfalen Düsseldorf Mettmann
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
Nessun dato

Partecipanti (1)